Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current Approaches to Transplantation for FLT3-ITD AML.

Current hematologic malignancy reports - 1 Feb 2020

Hunter Bradley D, Chen Yi-Bin

Abstract excerpt

PURPOSE OF REVIEW: This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS: Over the last decade, the routine use of HCT as consolidative therapy and the development of FLT3 TKIs have significantly improved remission rates and overall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to fms-Like Tyrosine Kinase 3
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Recurrence

Share to Transplantation, Homologous

Source

Identifiers

PMID: 32034660
DOI: 10.1007/s11899-020-00558-5

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current Approaches to Transplantation for FLT3-ITD AML.PMID 32034660Read ↗

Allogeneic transplant for FLT3 - ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplantSemantic proximity Read ↗

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSemantic proximity Read ↗

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.Semantic proximity Read ↗

Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments.Semantic proximity Read ↗

Allogeneic transplant for FLT3-ITD+ AML: room for improvement.Semantic proximity Read ↗

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read ↗

Targeting FLT3 mutations in AML: review of current knowledge and evidenceSemantic proximity Read ↗

The Future of Targeting FLT3 Activation in AML.Semantic proximity Read ↗

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.Semantic proximity Read ↗

Potential targeting of FLT3 acute myeloid leukemia.Semantic proximity Read ↗

Targeting FLT3 to treat leukemia.Semantic proximity Read ↗

An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.